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Identification of tipifarnib 
sensitivity biomarkers in T-cell 
acute lymphoblastic leukemia and 
T-cell lymphoma
Ruth Alonso-Alonso1,2,3,10, Rufino Mondéjar1,2,4,10, Nerea Martínez1,2, Nuria García-Diaz5, 
Cristina pérez1,2, David Merino6, Marta Rodríguez2,3, Anna esteve-codina8, Berta fuste7, 
Marta Gut7, Francis Burrows9, Catherine Scholz9, Jose Pedro Vaqué5, Antonio Gualberto9 & 
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Patients diagnosed with T-cell leukemias and T-cell lymphomas (TCLs) still have a poor prognosis 
and an inadequate response to current therapies, highlighting the need for targeted treatments. 
We have analyzed the potential therapeutic value of the farnesyltransferase inhibitor, tipifarnib, 
in 25 TCL cell lines through the identification of genomic and/or immunohistochemical markers of 
tipifarnib sensitivity. More than half of the cell lines (60%) were considered to be sensitive. Tipifarnib 
reduced cell viability in these T-cell leukemia and TCL cell lines, induced apoptosis and modified the 
cell cycle. A mutational study showed TP53, NOTCH1 and DNMT3 to be mutated in 84.6%, 69.2% 
and 30.0% of sensitive cell lines, and in 62.5%, 0% and 0% of resistant cell lines, respectively. An 
immunohistochemistry study showed that p-ERK and RelB were associated as potential biomarkers of 
tipifarnib sensitivity and resistance, respectively. Data from RNA-seq show that tipifarnib at IC50 after 
72 h downregulated a great variety of pathways, including those controlling cell cycle, metabolism, and 
ribosomal and mitochondrial activity. This study establishes tipifarnib as a potential therapeutic option 
in T-cell leukemia and TCL. The mutational state of NOTCH1, p-ERK and RelB could serve as potential 
biomarkers of tipifarnib sensitivity and resistance.
T-cell lymphoproliferative disorders are a very heterogeneous group of lymphoid neoplasms characterized by the 
clonal expansion of mature T-lymphocytes in bone marrow, blood or other tissues. They include peripheral T- cell 
lymphoma (PTCL) and T-cell acute lymphoblastic leukemia (T-ALL).
PTCL accounts for about 10% of all non-Hodgkin lymphomas (NHLs)1. It comprises a set of disorders that 
includes peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lym-
phoma (AITL), anaplastic lymphoma kinase (ALK-) positive and ALK-negative forms of anaplastic large cell 
lymphoma (ALCL), and enteropathy-associated TCL2. Despite the subtypes being very different at the molecular 
level, their treatment is basically similar, consisting of CHOP (cyclophosphamide, doxorubicin, vincristine, and 
prednisone) and Etopoxide, or a similar regimen. Therapeutic responses to this treatment show a current general 
5-year survival rate of only 10–30% and a rapid progression in some subtypes3–5.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy characterized by an 
accumulation of immature T-cell lymphoblasts in bone marrow and peripheral blood. In contrast with PTCL, 
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clinical progress has clearly improved in T-ALL; the 5-year survival rate is currently 65–70%6. These results high-
light the urgent need for alternative treatment strategies focusing on molecular characterization of individual 
cases that could identify potential candidates for targeted therapy.
The classification of T-cell lymphomas/leukemias is complex and requires the integration of information 
about clinical, pathological and genetic factors, morphology, immunohistochemistry (IHC), flow cytometry, 
cytogenetics, and molecular biology7,8. The relatively poor prognosis for PTCL4 is ultimately the consequence 
of our insufficient knowledge about the molecular pathogenesis of these tumors and the limited availability of 
therapeutic tools8.
Deregulated survival pathways and mutated genes have been partially characterized in PTCL. Genetic altera-
tions affecting TCR signaling operate as a common pathogenic mechanism in several TCL entities. Mutations in 
genes related to TCR co-stimulation and signaling were recently reported in a range of TCL entities, such as cuta-
neous T-cell lymphoma (CTCL), PTCL-NOS, AITL and ATLL (adult T-cell lymphoma/leukemia). Nonetheless, 
mutations in specific genes have a variable frequency in distinct entities9–13, and, for a given gene, the distribu-
tions of the mutations and their relative prevalence are quite variable.
The mutational landscape of T-ALL has recently been elucidated too. A variety of somatic mutations was 
described like, JAK1, JAK3, PTEN, IL7R and NRAS signaling proteins14,15. Other common oncogenic lesions are 
the loss of the CDKN2A (p16) locus and aberrant NOTCH1 signaling16–18. Activating mutations in JAK1, JAK3 
or IL7R lead to activation of the JAK/STAT pathway, resulting in the stimulation of proliferation and survival 
pathways in the leukemic cells and thereby the development of T-ALL19,20.
Aberrant activation of oncogenic Ras signal transduction is a very frequent finding in PTCL and T-ALL15,21. 
Mutations in RAS family genes induce constitutive activation of RAS-mitogen-activated protein kinase (MAPK), 
which activates several downstream effectors that play a role regulating a variety of cell functions, including cell 
growth, survival and differentiation. In view of these findings and the molecular landscape of PTCL and T-ALL, 
we were prompted to investigate the Ras mutations and MAPK pathway activation further. Farnesyltransferase 
inhibitors (FTIs) were designed to disrupt Ras farnesylation and the membrane localization necessary for Ras 
function. This work and other studies have demonstrated activity in neoplasms lacking mutant Ras22,23, suggest-
ing that it could inhibit farnesylation of multiple proteins, leading to the arrest of proliferation and the induction 
of apoptosis in a variety of preclinical models24,25.
Some phase I trials using tipifarnib have demonstrated its antineoplastic effects in solid tumors26,27 and leu-
kemia22. A variety of phase II trial has shown that it improves early survival when administered as maintenance 
therapy in patients in remission28. Administered as a single-agent, tipifarnib can produce antitumor effect in 
pretreated patients29.
The present study evaluates the effect of inhibiting FTase with tipifarnib30,31 in a panel of 25 TCL and T-ALL 
cell lines, enabling us to determine the therapeutic value of tipifarnib in these cell lines, and to identify biomark-
ers that could predict the response to this drug and to measure the dynamic effects on cell viability, apoptosis, cell 
cycle and gene expression. These observations could facilitate the development of personalized therapy in patients 
with TCL and T-ALL. The selected panel of 25 cell lines includes cell lines derived from a wide array of T-cell lym-
phoproliferative disorders, including T-cell acute lymphoblastic leukemia (T-ALL), cutaneous T-cell lymphoma 
(CTCL), anaplastic large cell lymphoma (ALCL) and adult T-cell lymphoma/leukemia (ATLL).
Results
T-cell leukemia/lymphoma cell lines are sensitive to tipifarnib. Tipifarnib was tested in 25 cell lines 
(Fig. 1). Tipifarnib readily achieved a peak concentration of 100 nM in the clinic. We categorized cell lines as sen-
sitive (<100 nM) or resistant (≥100 nM) based on IC50 values. With this classification, we found 60% of cell lines 
were sensitive to tipifarnib after 96 h (Fig. 1 and Supplementary Table S1).
Figure 1. Response of T-cell lymphoma cell lines to tipifarnib after 96 h. IC50 values (nM) of the cell lines, in 
ascending order. Data were treated and the image obtained with Graphpad Prism v5.
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Tipifarnib decreases cell viability, increases apoptosis and blocks cell cycle progression. Three 
of the most sensitive cell lines were selected to test cell viability and induction of apoptosis by flow cytometry. 
These cell lines differ in terms of subtype and mutational level. Jurkat and RPMI-8402 are derived from T-ALL, 
while SU-DHL-1 is derived from an ALCL. We found that the exposure to tipifarnib after 96 h at the previously 
calculated IC50 value reduced cell viability in these lines (Fig. 2a). We then analyzed the apoptotic effect and 
found this to be strong in SU-DHL-1 and RPMI-8402 cells (Fig. 2b). We decided to examine whether the drug 
had any effect on cell cycle progression. We found that tipifarnib was able to inhibit DNA synthesis and thereby 
block cell-cycle progression in G1 phase, preventing cells from reaching the cellular replication phase (G2 phase) 
(Fig. 2c). The strongest blockade was observed in the SU-DHL-1 cell line. The JURKAT cell line showed a smaller 
decrease in cell viability and a lower level of blockade of cell cycle progression, but these were nevertheless sig-
nificant (p < 0.05).
Tipifarnib does not change the T-cell phenotype. The T-cell phenotype in PTCL and T-ALL is at 
least partially regulated by precise mutational events that determine the expression of specific differentiation 
signatures32. Here we have examined whether tipifarnib induces changes in the T-cell phenotype. For this pur-
pose, we studied possible changes in the TH1 (IL2), TH2 (IL-4), Th17 (IL-17) and Treg (Foxp3) phenotypes 
Figure 2. Cell viability and induction of apoptosis in tipifarnib-sensitive cell lines (percentage relative to 
DMSO). Cell lines were incubated for 96 h at 1x IC50 (in purple) and 2x IC50 (in green) of tipifarnib, and DMSO 
(in black) as a vehicle. Each experiment was done in triplicate. Error bars are shown (s.e.m.) (a) Tipifarnib 
reduces cell viability. (b) Ability of tipifarnib to increase apoptosis in these lines. (c) Percentage of total DNA 
synthesis in exponentially growing tipifarnib-sensitive cell lines. Probabilities are those associated with Fisher’s 
exact tests.
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by analyzing changes in the expression of their markers in eight cell lines: MOLT-14, RPMI-8402, SU-DHL-1, 
L-82, HPB-ALL, HUT-78, JURKAT and HH. Those cytokines that allow the characterization of inflammatory, 
non-inflammatory and regulatory subpopulations were measured (Th1, Th2, Th17 and T Reg). No phenotypic 
changes were observed when cells were cultured in the presence of tipifarnib at IC50 and 2x IC50 (Supplementary 
Table S9). From this, we inferred that tipifarnib induces neither an increase in the regulatory phenotypes nor 
any differentiation into cells with inflammatory characteristics (Th1, Th17). Subsequent studies will determine 
whether the application of tipifarnib produces other changes in the cell lines, but we have verified that they do not 
produce modifications that lead to inflammatory or regulatory subtypes.
Mutational profile and transcriptomic signature are associated with tipifarnib sensitivity. In 
order to better understand the response to tipifarnib, we performed RNA-seq in a panel of 25 cell lines under 
basal conditions. In a first analysis, we selected a model that included the IC50 value (as a continuous variable), the 
mutational state of NOTCH1, ERK activation (p-ERK; by IHC), sex and cell subtype. In this case, the magnitude 
of the change represents a coefficient that increases with the IC50 value (Supplementary Table S8), which means 
that a positive value of change is related to resistance, and vice versa. For an exploratory view, a false discovery 
rate (FDR) of <0.25 was used33 to generate testable hypotheses. The results suggested that the TCR pathway, G 
protein-coupled receptor activity and G2/M checkpoints were correlated with highly sensitive cases, while NFkB 
activation by the TNFα, IFNγ and IFNα response, ribosome and p53 pathway were correlated with resistant cell 
lines (Supplementary Tables S5–S8).
We also analyzed some intracellular signaling pathways associated with T-cell leukemia/lymphoma under 
basal conditions by IHC. We found an association between ERK activation status and tipifarnib sensitivity 
(p = 0.046; Figs. 3 and 4b). Conversely, RelB expression was associated with resistance (p = 0.014) (Figs. 3 and 4c).
These results prompted us to focus our analysis on the RAS/MAPK pathway and other T-cell lymphoma 
pathways, such as TCR, JAK/STAT, NFAT and NFκB. We selected only cell lines with genomic data available from 
COSMIC or CCLE or generated by our group (Supplementary Table S3). We found that seven (53%) sensitive and 
three (37.5%) resistant cell lines harbored mutations in RAS genes (p > 0.05) (Fig. 4f). 52% and 33% of cells har-
bored mutations in RAS-guanine nucleotide exchange factors (GEFs) and RAS-GTPase activating protein (GAP) 
genes, respectively (p > 0.05, in both cases). The mutational state of the RAS, RAS-GEF and RAS-GAP genes was 
not associated with drug sensitivity (Figs. 3 and 4e), which may be explained by the potential effect of tipifarnib 
on multiple farnesylated genes and pathways. The mutational status of all the RAS-GEF genes was associated with 
ERK activation and negativity of RelB (p = 0.012 and p = 0.040, respectively).
Tipifarnib downregulates pathways involved in the development of TCL and T-ALL. To eluci-
date the consequences of farnesyltransferase inhibition in TCL and T-ALL cell lines, we performed RNA-seq in 
three highly sensitive cell lines (JURKAT, RPMI-8402 and SU-DHL-1). Differential gene expression was analyzed 
with and without tipifarnib. We detected 24 differentially expressed (DE) genes common to all three cell lines 
(Fig. 5a and Supplementary Table S8).
Two of these upregulated genes are related to damage response and the prevention of infection by retroviruses 
(ZMAT3 and ZC3HAV1, respectively). Several of the downregulated genes are involved in the cell cycle: UNG 
prevents mutagenesis; UHRF1 regulates chromatin structure and gene expression; SSRP1 affects nucleosome dis-
assembly and transcription elongation; MYBL2 influences cell-cycle progression; MCM2 and MCM3 are involved 
in replication. Other deregulated genes are closely related to enzymatic and mitochondrial activity (SHMT2, 
MTHFD1 and CTPS1). The heat shock response genes, HSPD1, HSPA9 and HSP90AB1, are other downregulated 
genes.
GSEA was performed under more stringent conditions (FDR < 0.05; Supplementary Tables S5–8). Tipifarnib 
downregulated cell cycle, protein localization to cell membrane, metabolism, and ribosomal and mitochondrial 
activity. Regarding the REACTOME database, tipifarnib downregulated 137 pathways (Supplementary Table S6), 
and the GO enrichment analysis showed 32 and 975 positive and negative enrichment pathways, respectively 
(Supplementary Table S7). The most representative downregulated pathways, according to the degree of KEGG 
enrichment34,35, are shown in Fig. 5b. Analyzing pathways involved in T-cell development, we detected that tipi-
farnib decreased MYC targets and mTORC1 and MAPK signaling.
Discussion
T-cell leukemia/lymphomas account for between 10 and 15% of all lymphoid tumors and, in most cases, are 
characterized by an unfavorable prognosis. Despite our growing knowledge about molecular pathogenesis and 
the diversity of T-cell leukemia/lymphoma cases, the first line of treatment remains similar in all subgroups. The 
effectiveness of this treatment is quite limited, with only around 25% of patients remaining alive without disease 
5 years after the initial diagnosis of TCL or T-ALL6,36.
Considerable efforts are being made to identify subclasses of TCL and T-ALL that are susceptible to therapy 
with specific protocols and to distinguish targetable mutated genes and/or activated pathways. Previous studies 
by several groups have identified the most commonly deregulated mechanisms driving tumorigenesis in TCL and 
T-ALL, and provided a useful tool for analyzing the interaction between gene mutations and the activation of key 
survival pathways8,19,20,37.
Given the important role in TCR signaling in neoplastic T-cells, we decide to study the RAS/MAPK pathway 
and its members to elucidate the genomic basis of TCL and T-ALL. Aberrant activation of the oncogenic RAS sig-
nal transduction is commonly observed in these entities. FTIs were initially developed to inhibit RAS activation 
by blocking farnesylation38. Some clinical trials27,29,39 showed limited activity, probably due to the ability of RAS 
to become activated through geranylgeranylation40, which is an alternative process to farnesylation.
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Here we report the effectiveness of the farnesyltransferase inhibitor tipifarnib in a panel of 25 TCL and T-ALL 
cell lines, integrating in vitro sensitivity data with genomic and immunohistochemical biomarker analysis. Our 
study suggests that tipifarnib could be a potential therapeutic option in T-cell leukemia/lymphomas, given that 
Figure 3. Mutational landscape of RAS/MAPK, JAK/STAT, TCR pathways and T cell lymphoma-related genes 
in TCL cell lines and IHC markers. Cell lines were grouped into highly sensitive (in green) and less sensitive 
(in red) in the upper part of the table. Missense mutations are marked in blue, truncated mutations in red, and 
splicing mutations in orange in the upper part of the table. In the part referring to IHC, dark blue, light blue and 
green correspond to positive labeling for TP53, CD30 and p-ERK, respectively.
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the majority of lines were sensitive to tipifarnib (60%) at clinically achievable concentrations (i.e., IC50 < 100 nM 
after 96 h).
Analyzing the differences between sensitive and resistant cell lines we found TP53, NOTCH1 and DNMT3A to 
be mutated in 84.6%, 69.2% and 30.0% of cells in sensitive cell lines, respectively, in contrast to resistant cell lines, 
in which the mutational frequencies were much lower (62.5% for TP53, and 0% for NOTCH1 and DNMT3A) 
(Figs. 3 and 4a). The association between the mutational status of NOTCH1 and tipifarnib sensitivity was statisti-
cally significant. This could be an interesting target therapy option in these entities since aberrant NOTCH1 sign-
aling is the predominant oncogenic lesion involved in the pathogenesis of T-ALL14,41, and NOTCH1 interference 
has been proposed by various researchers17,41.
We also compared the activation status of some key intracellular signaling pathways associated with T-cell 
leukemia/lymphoma. We found an association between ERK activation, measuring p-ERK expression, and tipi-
farnib sensitivity (Figs. 3 and 4b). Conversely, RelB upregulation, probably reflecting activation of the alternative 
NFκB pathway, was associated with tipifarnib resistance (Figs. 3 and 4c), suggesting that the mutational status 
Figure 4. Mutational stage of some biomarkers of tipifarnib sensitivity and resistance in TCL cell lines. (a) 
NOTCH1; (b) p-ERK; (c) RELB; (d) CD30; (e) RAS superfamily; (f) RAS genes. Green boxes represent the most 
tipifarnib-sensitive cell lines; red boxes indicate cell lines with higher IC50 (resistant). Graphs were obtained by 
Graphpad Prism v5 and the probability associated with Fisher’s exact test.
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of NOTCH1 and the activation of ERK could serve as potential biomarkers of sensitivity to tipifarnib, and the 
positivity of RelB (by IHC) could be a biomarker of resistance to the drug. Other studied markers, such as CD30, 
showed no such significant associations (Fig. 4d).
Given the association between ERK activation and tipifarnib sensitivity, we focused our attention on the RAS/
MAPK pathway and other T-cell leukemia/lymphoma-related pathways, such as TCR, JAK/STAT, NFAT and 
NFκB, which are known to be involved in T-cell leukemia/lymphoma8,11,13,42. Considering RAS members, we 
found that seven sensitive (46%) and three resistant (37.5%) cell lines harbored mutations in RAS genes (not 
significant (n.s.)); eight sensitive (61%) and three resistant (37.5%) cell lines harbored mutations in RAS-guanine 
nucleotide exchange factors (GEFs) (n.s.) and five sensitive (38%) and two resistant (25%) cell lines harbored 
mutations in RAS-GTPase-activating protein (GAP) genes (n.s.). The mutational state of the RAS, RAS-GEF and 
RAS-GAP genes was not associated with tipifarnib sensitivity. The mutational state of all the RAS-GEF genes was 
associated with ERK activation and RelB negativity (p = 0.012 and p = 0.021, respectively).
Under basal conditions, RNAseq analysis of 25 cell lines indicated that the TCR pathway, G protein-coupled 
receptor activity and G2/M checkpoints were correlated with greater sensitivity to tipifarnib, while NFkB activa-
tion by TNFα, IFNγ and IFNα response, ribosome and p53 pathway were correlated with resistance. These results 
replicate and confirm our previous observations that associated mutational status and pathway activation with 
tipifarnib sensitivity.
To improve our understanding of the biological mechanism of action of tipifarnib, we performed RNA-seq in 
three of the most sensitive cell lines (JURKAT, RPMI-8402, and SU-DHL-1). We detected more than 300 differ-
entially expressed genes (Supplementary Tables S5–S7), of which 24 changed their expression consistently in the 
three cell lines (Supplementary Table S8). GSEA of these data showed that tipifarnib downregulated cell-cycle, 
protein localization to membranes, metabolism, and ribosomal and mitochondrial activity. These findings con-
cerning cell-cycle downregulation and apoptosis were confirmed by cytometry assays (Fig. 2). In the REACTOME 
database, tipifarnib downregulated 137 pathways (Supplementary Table S6), and the GO enrichment analysis 
showed 32 positive and 975 negative enrichment pathways (Supplementary Table S7).
The mammalian target of rapamycin (mTOR) is another commonly activated pathway in TCL and T-ALL43–45. 
As part of the mTORC1 and mTORC2 complexes, mTOR has key roles in several pathways involved in human 
cancer, which has stimulated interest in mTOR inhibitors. This study has shown that tipifarnib decreases MYC 
targets and mTORC1 and MAPK signaling, especially in the JURKAT and RPMI-8402 cell lines. A potential role 
mediating mTORC inhibition as a result of administering FTI has been proposed for RAS homologue enriched 
Figure 5. DE genes and pathways commonly regulated by tipifarnib in JURKAT (pink), RPMI-8402 (yellow) 
and SU-DHL-1 (blue) cell lines. (a) 24 genes commonly downregulated (left) and upregulated (right) with 
tipifarnib, with adjusted values of p < 0.05. Bars show log-fold change. (b) Pathways downregulated by 
tipifarnib. Normalized enrichment score (p < 0.05; FDR < 5%). Bars show log-fold change.
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in brain (Rheb), which is a farnesylated small GTPase, a key protein in the Rheb-Notch-Rheb loop, that positively 
regulates mTOR signaling46–49.
This study suggests that tipifarnib is a potential therapeutic option in T-cell lymphomas and T-cell acute 
lymphoblastic leukemia. The results of our study suggest that the mutational state of NOTCH1 and the activation 
of ERK could serve as potential biomarkers of tipifarnib sensitivity, and a high level of RelB expression could be a 
biomarker of resistance to the drug. These results require validation in clinical samples or PDXs.
Material and Methods
Cell lines. We included 25 TCL and T-ALL cell lines representing tumor types such as T-cell acute lymph-
oblastic leukemia/lymphoma (T-ALL, n = 18), anaplastic large cell lymphoma (ALCL, n = 3), cutaneous T-cell 
lymphoma (CTCL, n = 3), and adult T-cell lymphoblastic leukemia (ATLL, n = 1) (Supplementary Table S2, 
from8). All cell lines were purchased or authenticated before use and were tested for mycoplasma (MycoAlert 
mycoplasma detection kit; Lonza, Basel, Switzerland).
Cell culture. CCRF-CEM, HH, HUT-78, LOUCY, MJ, MOLT-4, SU-DHL-1 and SUP-T1 cell lines were pur-
chased from the American Type Culture Collection (ATCC) and cultured with Roswell Park Memorial Institute 
(RPMI) 1640 Medium (Thermo Fisher Scientific) containing 10% fetal bovine serum (Gibco), except for the MJ 
cell line, which was cultured with Gibco Iscove’s Modified Dulbecco’s Media (IMDM) medium (Thermo Fisher 
Scientific) containing 20% fetal bovine serum.
BE-13, DND-41, HD-MAR-2, HPB-ALL, HSB-2, JURKAT, KE-37, L-82, MHH-TALL-2, MOLT-14, MOLT-
16, P12-ICHIKAWA, PF-382, RPMI-8402, SR-786 and TALL-1 were purchased from the DSMZ German 
Collection of Microorganisms and Cell Cultures. Except for HSB-2, they were cultured with Roswell Park 
Memorial Institute (RPMI) 1640 Medium containing different proportions of fetal bovine serum: 10% for DND-
41, HD-MAR-2, HPB-ALL, JURKAT, KE-37, L-82, MOLT-14, MOLT-16, P12-ICHIKAWA, PF-382 and RPMI-
8402; 20% for BE-13 and MHH-TALL-2; 15% for SR-786 and TALL-1. HSB-2 was cultured with Gibco Iscove’s 
Modified Dulbecco’s Media (IMDM) medium containing 10% fetal bovine serum.
MyLa was purchased from the European Collection of Authenticated Cell Cultures (ECACC) and was cul-
tured with Roswell Park Memorial Institute (RPMI) 1640 Medium containing 10% fetal bovine serum.
All cells were cultured in CO2 incubators at 37 °C in an atmosphere containing 5% CO2.
Drug sensitivity. All cell lines were tested for tipifarnib sensitivity in two steps, for which purpose they 
were cultured in appropriate medium in T96 multi-well plates (Falcon 96-well flat-bottom TC-treated Imaging 
Microplates). Individual optimal cell line seeding densities were determined before deriving growth curves with 
increasing concentrations of tipifarnib (1, 3, 10, 30, 100 and 300 nM, and 1, 3 and 10 μM) using DMSO as the 
vehicle for 96 h. Six replicates of all experiments were carried out, and IC50 (half-maximal response) values were 
calculated. Tipifarnib was provided by Kura Oncology (San Diego, CA, USA). Growth curves were derived and 
IC50 values determined using the Cell Titer-Glo Luminescent Cell Viability Assay from Promega (Fitchburg, WI, 
USA) at 0, 24, 72 and 96 h. IC50 values were calculated with Graphpad Prism v5 (La Jolla, CA, USA).
Apoptosis and cell-cycle analysis. Three of the most sensitive cell lines were subjected to apopto-
sis and cell-cycle analysis. Flow cytometry assays were used for both analyses, using a Flow Cellect Annexin 
Red Kit (Millipore, Burlington, MA, USA) and a Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay 
Kit (Invitrogen, C10634), following the manufacturers’ instructions. Cells were seeded in 12-well plates (VWR 
International, 10062–894) and incubated for 24 h at 37 °C in a humidified atmosphere of 5% CO2. Cells were 
maintained in standard conditions for 24 h, after which they were exposed to IC50 and 2x IC50 values of tipifarnib 
and DMSO as a vehicle for 96 h. The positive and negative controls for the next analysis were included. To identify 
dead and apoptotic cells, 100 μL of Annexin Red Working Solution were added to each 100 μL of cell suspension 
and samples were incubated for 15 min at 37 °C. Samples were washed and resuspended in Assay Buffer HSC and 
then 5 μL of 7-ADD were added. Samples were incubated at room temperature (RT) for 5 minutes in the dark 
before analysis by Fluorescence-Activated Cell Sorting (FACS). Double-positive cells (Annexin-V and 7-ADD) 
were considered in the late apoptotic stage or necrotic cells, whereas cells that were positive for Annexin-V but 
negative for 7-ADD were those in early-stage apoptosis; in this study, we were interested in these early apoptotic 
cells. To assess the effects on DNA synthesis, cells were grown in each appropriate medium and, after treatment 
with tipifarnib, incubated for a further 2 h with EdU (5-ethynyl-2′-deoxyuridine), which is a nucleoside analog 
of thymidine that is incorporated into the DNA during active DNA synthesis (Click-iT Plus EdU Alexa Fluor 647 
Flow Cytometry Assay, Invitrogen, C10634). Immediately afterwards, cells were prepared for cytometry following 
the manufacturer’s recommendations. To calculate the percentage blockade of tipifarnib in the G0 phase and to 
prevent these cell lines from entering the G2 phase of replication, the percentage inhibition of tipifarnib with 
respect to DMSO was measured.
Genomic and IHC data. As previously described by our group8, we obtained genomic data from 
genomic repositories from T-cell lymphoma/leukemia cell lines. Specifically, we combined genomic data 
from CCLE (Cancer Cell Line Encyclopedia, http://www.broadinstitute.org/ccle, accessed April 30, 2017), 
COSMIC Cell Lines Project (http://cancer.sanger.ac.uk/cell_lines, accessed April 30, 2017), EGAS00001000268 
(European Genome-Phenome Archive, https://www.ebi.ac.uk/ega/), exomes produced previously by our 
group (Supplementary Table S3), and targeted sequencing of 16 T-cell leukemia/lymphoma-associated genes8 
(Supplementary Table S4). Variants were called using MiSeq Reporter and RUbioSeq.50, employing the default 
settings, and were visually inspected with the Integrative Genomics Viewer (www.broadinstitute.org/igv/). 
Variants were annotated using the Variant Effect Predictor (GRCh37, http://grch37.ensembl.org/Tools/VEP). 
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Known SNPs with an allelic frequency greater than 1% in public databases (dbSNP138, 1000 Genomes Project, 
Exome Sequencing Project, Exome Aggregation Consortium) were filtered out.
Stranded mRNA library preparation and sequencing. As previously described by Mondejar et al.8, 
total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer’s protocol. Total RNA 
was assayed for quantity and quality using the Qubit RNA BR or HS Assay Kit on the Qubit 2.0 Fluorometer (Life 
Technologies), and the RNA 6000 Nano Assay on a Bioanalyzer 2100 (Agilent). The RNASeq libraries were pre-
pared using TruSeq Stranded mRNA LT Sample Preparation Kit (Illumina, Inc., Rev. E, October 2013). Briefly, 
total RNA (500 ng) was enriched for the mRNA fraction and fragmented by divalent metal cations at high tem-
perature (the resulting RNA fragments were 80–250 nt, with a maximum peak of 130 nt). To achieve direction-
ality, the second-strand cDNA synthesis was performed in the presence of dUTP. Mondejar et al.8 described how 
the blunt-ended double-stranded cDNA was 3′adenylated and Illumina indexed adapters were ligated. The liga-
tion product was enriched over 15 PCR cycles and the final library was validated on an Agilent 2100 Bioanalyzer 
with the DNA 7500 assay (Agilent). Libraries were sequenced on HiSeq2000 (Illumina, Inc.) in paired-end mode 
with a read length of 2 × 76 bp using a TruSeq SBS Kit v4 in a fraction of a sequencing v4 flow cell lane, following 
the manufacturer’s protocol. Image analysis, base calling and quality scoring of the run were processed using the 
manufacturer’s Real Time Analysis (RTA 1.18.66.3) software, followed by generation of FASTQ sequence files.
RNA-seq data processing and analysis. RNA-seq was performed in 25 cell lines under basal culture 
conditions. RNA-seq paired-end reads were mapped against the human reference genome (GRCh38) using STAR 
version 2.5.3a51 with ENCODE parameters for long RNA. Annotated genes (GENCODE version 27) were quanti-
fied using RSEM version 1.3.052 with default parameters. Differential expression was analyzed with limma-voom53 
adjusted for sex, cell subtype and 18 other hidden factors detected by surrogate variable analysis (sva). The IC50 
was considered as a continuous variable, and only genes with at least 1 cpm in 10 samples or more were selected 
for the analysis.
To further elucidate the consequences of farnesyltransferase inhibition in TCL and T-ALL cell lines, RNA-seq 
was performed in three cell lines (RPMI-8402, SU-DHL-1 and JURKAT) treated with tipifarnib for 72 h at IC50 
and DMSO in three biological replicates. RNA-seq reads were mapped and genes were annotated as described 
above. Principal component analysis of the ‘rlog’-transformed expression data was done using the top 500 most 
variable genes with the ‘prcomp’ R function and ‘ggplot2’ R library. Two outlier samples belonging to DMSO_
SUDHL1 and TIPI_SUDHL1 were removed. Differential expression was analyzed with DESeq2 version 1.1054 
for each cell line separately. Heatmaps with the top 50 differentially expressed genes were generated with the 
‘pheatmap’ R package. Gene set enrichment analysis (GSEA) was performed from a background of > 5000 gene 
sets of the Hallmark collection of the Molecular Signatures Database (MSigDB), curated (C2 collection: KEGG, 
BIOCARTA, REACTOME) and Gene Ontology (GO) gene sets (C5 collection). Expression data have been 
deposited in the Sequence Read Archive (SRA) under BioProject accession reference PRJNA603759.
Phenotypic characterization. The expression of the markers IL-2, IL-4, IFN-g, IL-17, RORγT and Foxp3 
was tested by FACS in eight cell lines (MOLT-14, RPMI-8402, SU-DHL-1, L-82, HPB-ALL, HUT-78, JURKAT 
and HH), enabling possible changes in the TH1/TH2/Treg/Th17 phenotypes to be studied. Cell lines were incu-
bated for 96 h at 1x and 2x the IC50 of tipifarnib and DMSO in plates of T12 wells (VWR International, 10062-
894). All experiments were done in triplicate.
Statistical analysis. The chi-square or Fisher exact test were used to determine the significance of associa-
tions between the presence or absence of markers and sensitivity. Estimates were considered statistically signifi-
cant for two-tailed values of p < 0.05. All analyses were carried out using IBM SPSS for Windows version 20 (IBM 
Corp., Armonk, NY, USA).
Data availability
The datasets generated during the current study are available in the Sequence Read Archive (SRA) 
under  BioProject accession reference PRJNA603759. We consulted and obtained genomic data from genomic 
repositories from T-cell lymphoma/leukemia cell lines (see Genomic and IHC data in Materials and Methods 
section).
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